Interim Management Statement

FINSBURY WORLDWIDE PHARMACEUTICAL TRUST PLC                  

    Interim Management Statement - 3 months to 31 December 2007 (unaudited)    

Finsbury Worldwide Pharmaceutical Trust PLC invests in pharmaceutical and
biotechnology companies worldwide with the aim of achieving a high level of
capital growth.

The 3 month period ending 31 December 2007 was a volatile one for the
pharmaceutical sector which saw the Company's undiluted net asset value per
share fall by 1.0% compared to a fall of 0.4% in the Company's benchmark, the
Datastream World Pharmaceutical and Biotechnology Index measured in sterling
terms on a total return basis. The Company's share price fell by 1.4% during
the three-month period. For the calendar year as a whole, however, the
Company's undiluted net asset value per share rose by 4.1% and the share price
rose by 2.7%, compared to a fall of 0.3% in the benchmark index.

Following a quiet October, the undiluted net asset value per share rose by 1.5%
in November despite a broader market sell-off amid concerns about deteriorating
credit quality, slowing global growth and further declines in the US housing
market; the Company underperformed its benchmark, however, due to its
overweight position in biotechnology companies. Performance in December was
disappointing where Biogen Idec, a significant holding in the Investment
Portfolio, announced that following its decision to put itself up for sale, no
significant offers had been received; Biogen Idec's share price fell by 25% as
a result.

During the period a total of 1,117,037 shares were repurchased for cancellation
at a cost of £5,510,000 (including expenses). All of the 5,192,100 shares held
in treasury, as at 31 January 2008, were cancelled.

Since the period end, to the end of January 2008, the Company's undiluted net
asset value per share fell by 5.0% compared to a fall in the benchmark index of
4.2%. The Company's share price fell by 4.3% in the same period.

Trust Characteristics

                           31 December 2007          30 September 2007         
                                                                               
Number of holdings         43                        42                        
                                                                               
Net assets (£m)            259.2                     267.9                     
                                                                               
Net yield                  0.6%                      0.6%                      
                                                                               
Gearing (AIC basis)        101                       106                       
                                                                               
Share price (p)            495.75                    503.00                    
                                                                               
NAV (p) -undiluted         545.40                    550.81                    
                                                                               
NAV (p) diluted: warrants  530.38                    535.09                    
                                                                               
NAV (p) - fully diluted    527.55                    532.51                    
for                                                                            
                                                                               
warrants and treasury                                                          
shares                                                                         
                                                                               
(Discount)/premium         (9.1%)                    (8.7%)                    
(undiluted)                                                                    
                                                                               
(Discount/premium(diluted  (6.5%)                    (6.0%)                    
- warrants)                                                                    
                                                                               
(Discount/premium (fully   (6.0%)                    (5.5%)                    
diluted)                                                                       
                                                                               
Warrant price (p)          71.00                     85.50                     

Source: Frostrow Capital LLP


10 Largest Investments

Name                                 % of                      % of           
                             investment portfolio      investment portfolio    
                              at 31 December 2007      at 30 September 2007   
                                                                              
Genentech Inc                         5.5                     5.3                      
                                                                              
Schering-Plough                       5.4                     4.6                      
                                                                              
Novartis                              5.0                     4.7                      
                                                                              
Genzyme                               4.8                     3.7                      
                                                                              
Amgen                                 4.6                     5.2                      
                                                                              
Abbott Laboratories                   4.5                     4.0                      
                                                                              
Roche                                 4.5                     3.5                      
                                                                              
Takeda Pharmaceutical                 4.2                     4.6                      
                                                                              
Gen-Probe                             4.0                     5.5                      
                                                                              
Biogen Idec                           3.7                     1.6                      
                                                                              
Total                                46.2                    42.7                     

Source: Frostrow Capital LLP

Sector Analysis

                                      % of                       % of           
                              investment portfolio       investment portfolio   
                              at 31 December 2007        at 30 September 2007   
                                                                                
Large capitalisation                  62.4                       58.0           
                                                                                
Small capitalisation                  37.6                       42.0           
                                                                                
Total                                100.0                      100.0           

Source: Frostrow Capital LLP

Geographical Analysis

                                     % of                       % of           
                             investment portfolio       investment portfolio   
                             at 31 December 2007        at 30 September 2007   
                                                                               
North America                        70.0                       72.3           
                                                                               
Europe                               14.6                       12.6           
                                                                               
Japan                                15.4                       15.1           
                                                                               
Total                               100.0                      100.0           

Source: Frostrow Capital LLP

Total Return Performance

                3 Months        1 Year          3 Years         5 Years        
                                                                               
Share price     -1.4%           +2.7%           +12.2%          +43.1%         
                                                                               
NAV Fully       -0.9%           +4.1%           +16.2%          +46.6%         
diluted                                                                        
                                                                               
Benchmark*      -0.4%           -0.3%           +21.1%          +28.1%         

Source: NAV (total return; fully diluted) and Share Price (total return)
Fundamental Data. Benchmark - Thomson Financial Ltd.

* Benchmark - Datastream World Pharmaceutical and Biotechnology Index measured
in sterling terms on a total return basis.

Past performance is not a guide to future performance.

Other than as described above the Board is not aware of any events during the
period from 1 October 2007 to the date of this statement which would have a
material impact on the financial position of the Company.

This interim management statement is available on the Company's website 
www.finsburywp.com.

The Company's Net Asset Value per share is announced daily and is available,
together with the share price, on the TrustNet website at www.trustnet.com

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

15 February 2008